The company received an FDA Complete Response Letter rejecting its drug application due to significant manufacturing and product safety concerns (leachables data, toxicology assessments, manufacturing deficiencies), resulting in stock price decline and triggering a securities investigation.
The company announced successful Phase 3 trial results meeting primary endpoints with favorable safety and efficacy data. GTx-104 demonstrated superior dose intensity, reduced hypotension incidence, fewer ICU readmissions, and better functional outcomes compared to oral nimodipine, supporting advancement toward regulatory approval for a rare disease with significant unmet medical needs.
The company is advancing a late-stage clinical asset with FDA orphan drug designation and has achieved a PDUFA target date for review, indicating regulatory progress. The drug has been administered in over 200 patients with good tolerability, and the company is presenting at a major healthcare conference, demonstrating investor engagement and confidence in the pipeline.
Articles that tag GRCE but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
